Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for Active Pyoderma Gangrenosum Ulcers in Japan
NCT03311464Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Oct 2017
- Primary completion
- Aug 2019
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of adalimumab in pyoderma gangrenosum (PG), sponsored by AbbVie Inc.. Started Oct 2017; status: completed.
02
Drugs
03
Conditions
pyoderma gangrenosum (PG)
Beyond the preview
Go deeper on NCT03311464.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03311464.